Experimental treatment of multiple myeloma in the era of precision medicine

References

• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372:2229–2234.
   PubMed Web of Science ®Google Scholar
• Rosland GV, Engelsen AS. Novel points of attack for targeted cancer therapy. Basic Clin Pharmacol Toxicol. 2015;116:9–18.
   PubMed Web of Science ®Google Scholar
• Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015;64:S16–S21.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015;526:361–370.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2011;104:392–398.
   PubMed Web of Science ®Google Scholar
• Rossi M, Di Martino MT, Morelli E, et al Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12:757–767.
   PubMed Web of Science ®Google Scholar
• Rossi M, Botta C, Correale P, et al Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther. 2013;13(Suppl 1):S83–S93.
   PubMed Web of Science ®Google Scholar
• Cottini F, Anderson K. Novel therapeutic targets in multiple myeloma. Clin Adv Hematol Oncol. 2015;13:236–248.
   PubMedGoogle Scholar
• Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43:732–741.
   PubMed Web of Science ®Google Scholar
• Rossi M, Amodio N, Di Martino MT, et al From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets. 2013;14:1144–1149.
   PubMed Web of Science ®Google Scholar
• Misso G, Zappavigna S, Castellano M, et al Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther. 2013;13(Suppl 1):S95–S109.
   PubMed Web of Science ®Google Scholar
• Calimeri T, Battista E, Conforti F, et al A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011;25:707–711.
   PubMed Web of Science ®Google Scholar
• Tassone P, Neri P, Burger R, et al Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets. 2012;12:814–822.
   PubMed Web of Science ®Google Scholar
• Blotta S, Jakubikova J, Calimeri T, et al Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012;120:5002–5013.
   PubMed Web of Science ®Google Scholar
• Hamasaki M, Hideshima T, Tassone P, et al Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005;105:4470–4476.
   PubMed Web of Science ®Google Scholar
• Rosean TR, Tompkins VS, Tricot G, et al Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014;59:188–202.
   PubMed Web of Science ®Google Scholar
• Walker RE, Lawson MA, Buckle CH, et al Myeloma bone disease: pathogenesis, current treatments and future targets. Br Med Bull. 2014;111:117–138.
   PubMed Web of Science ®Google Scholar
• Yasui H, Hideshima T, Hamasaki M, et al SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005;106:706–712.
   PubMed Web of Science ®Google Scholar
• Tassone P, Galea E, Forciniti S, et al The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol. 2002;21:867–873.
   PubMed Web of Science ®Google Scholar
• Yap TA, Olmos D, Molife LR, et al Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs. 2011;20:1293–1304.
   PubMed Web of Science ®Google Scholar
• Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J. 2015;5:e282.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Dingli D, Roy V, et al Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–376.
   PubMed Web of Science ®Google Scholar
• Van Laar R, Flinchum R, Brown N, et al Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. BMC Med Genomics. 2014;7:25.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, et al A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–2284.
   PubMed Web of Science ®Google Scholar
• Chen T, Berno T, Zangari M. Low-risk identification in multiple myeloma using a new 14-gene model. Eur J Haematol. 2012;89:28–36.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–2869.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–348.
   PubMed Web of Science ®Google Scholar
• Kryukova E, Kryukov F, Hajek R. Centrosome amplification and clonal evolution in multiple myeloma: short review. Crit Rev Oncol Hematol. 2015;98:116–121. DOI:10.1016/j.critrevonc.2015.10.019
   PubMed Web of Science ®Google Scholar
• Johnson SK, Heuck CJ, Albino AP, et al The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol. 2011;94:321–333.
   PubMed Web of Science ®Google Scholar
• Kronke J, Udeshi ND, Narla A, et al Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–305.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–309.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Reme T, Leonard W, et al Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Mol Cancer Ther. 2012;11:2685–2692.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–917.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Carter SL, et al Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91–101.
   PubMed Web of Science ®Google Scholar
• Cottini F, Hideshima T, Suzuki R, et al Synthetic lethal approaches exploiting DNA damage in aggressive myeloma. Cancer Discov. 2015;5:972–987.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Lehners N, Capper D, et al Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3:862–869.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yan W, Bai Y, et al Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo. Oncol Rep. 2015;33:448–456.
   PubMed Web of Science ®Google Scholar
• Agnelli L, Tassone P, Neri A. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opin Biol Ther. 2013;13(Suppl 1):S55–S68.
   PubMed Web of Science ®Google Scholar
• Lionetti M, Agnelli L, Lombardi L, et al MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets. 2012;12:823–837.
   PubMed Web of Science ®Google Scholar
• Lionetti M, Musto P, Di Martino MT, et al Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013;19:3130–3142.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Meissner T, Moreaux J, et al miRNAs in multiple myeloma - a survival relevant complex regulator of gene expression. Oncotarget. 2015;6:39165–39183.
   PubMed Web of Science ®Google Scholar
• Tagliaferri P, Rossi M, Di Martino MT, et al Promises and challenges of microRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12:838–846.
   PubMed Web of Science ®Google Scholar
• Rossi M, Amodio N, Di Martino MT, et al MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol. 2014;15:459–467.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Amodio N, Tassone P, et al. Functional analysis of microRNA in multiple myeloma. Methods Mol Biol. 2015:S125–S137. DOI:10.1517/14712598.2013.796356
   PubMedGoogle Scholar
• Amodio N, Di Martino MT, Neri A, et al Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13(Suppl 1):S125–S137.
   PubMed Web of Science ®Google Scholar
• Gulla A, Di Martino MT, Gallo Cantafio ME, et al. A 13 mer LNA-i-miR-221 inhibitor restores drug-sensitivity in melphalan-refractory multiple myeloma cells. Clin Cancer Res. 2013;19(8):2096–2106. DOI:10.1158/1078-0432.CCR-12-3325
   PubMed Web of Science ®Google Scholar
• Leone E, Morelli E, Di Martino MT, et al Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013;19:2096–2106.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Gulla A, Gallo Cantafio ME, et al In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One. 2014;9:e89659.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Gulla A, Cantafio ME, et al In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget. 2013;4:242–255.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Roccaro AM, Rombaoa C, et al LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012;120:1678–1686.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Zhu D, et al miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res. 2014;74:1801–1813.
   PubMed Web of Science ®Google Scholar
• Du J, Liu S, He J, et al MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget. 2015;6:14993–15007.
   PubMed Web of Science ®Google Scholar
• Feng M, Luo X, Gu C, et al Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. J Drug Target. 2015;23:59–66.
   PubMed Web of Science ®Google Scholar
• Leotta M, Biamonte L, Raimondi L, et al A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol. 2014;229:2106–2116.
   PubMed Web of Science ®Google Scholar
• Amodio N, Bellizzi D, Leotta M, et al miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013;12:3650–3662.
   PubMed Web of Science ®Google Scholar
• Raimondi L, Amodio N, Di Martino MT, et al Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget. 2014;5:3039–3054.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Campani V, Misso G, et al In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 2014;9:e90005.
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Thompson B, et al MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669–6680.
   PubMed Web of Science ®Google Scholar
• Shen X, Guo Y, Yu J, et al. miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor. Clin Exp Med. 2015:1–10. DOI:10.1007/s10238-015-0355-4
   PubMed Web of Science ®Google Scholar
• Yang Y, Li F, Saha MN, et al miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 2015;21:2399–2411.
   PubMed Web of Science ®Google Scholar
• Palagani A, Op De Beeck K, Naulaerts S, et al. Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. PLoS One. 2014;9:e113842.
   PubMed Web of Science ®Google Scholar
• Jagannathan S, Vad N, Vallabhapurapu S, et al MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia. 2015;29:727–738.
   PubMed Web of Science ®Google Scholar
• Morelli E, Leone E, Cantafio ME, et al Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29:2173–2183.
   PubMed Web of Science ®Google Scholar
• Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, et al Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica. 2013;98:640–648.
   PubMed Web of Science ®Google Scholar
• Misso G, Di Martino MT, De Rosa G, et al Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194.
   PubMedGoogle Scholar
• Di Martino MT, Leone E, Amodio N, et al Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18:6260–6270.
   PubMed Web of Science ®Google Scholar
• Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011;18:1111–1120.
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Lingjaerde OC, Russnes HG, et al Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer. 2014;14:299–313.
   PubMed Web of Science ®Google Scholar
• Guzzi PH, Agapito G, Milano M, et al. Methodologies and experimental platforms for generating and analysing microarray and mass spectrometry-based omics data to support P4 medicine. Brief Bioinform. 2015. DOI:10.1093/bib/bbv076
   PubMedGoogle Scholar
• Roy S, Guzzi PH. Biological network inference from microarray data, current solutions, and assessments. Methods Mol Biol. 2015:1–13. DOI:10.1007/7651_2015_284
   Google Scholar
• Yan Z, Shah PK, Amin SB, et al Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res. 2012;40:e135.
   PubMed Web of Science ®Google Scholar
• Huang GT, Athanassiou C, Benos PV. mirConnX: condition-specific mRNA-microRNA network integrator. Nucleic Acids Res. 2011;39:W416–W423.
   PubMed Web of Science ®Google Scholar
• Afshar AS, Xu J, Goutsias J. Integrative identification of deregulated miRNA/TF-mediated gene regulatory loops and networks in prostate cancer. PLoS One. 2014;9:e100806.
   PubMed Web of Science ®Google Scholar
• Van Iterson M, Bervoets S, De Meijer EJ, et al Integrated analysis of microRNA and mRNA expression: adding biological significance to microRNA target predictions. Nucleic Acids Res. 2013;41:e146.
   PubMed Web of Science ®Google Scholar
• Bryan K, Terrile M, Bray IM, et al Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis. Nucleic Acids Res. 2014;42:e17.
   PubMed Web of Science ®Google Scholar
• Nazarov PV, Reinsbach SE, Muller A, et al Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function. Nucleic Acids Res. 2013;41:2817–2831.
   PubMed Web of Science ®Google Scholar
• Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004;20:3705–3706.
   PubMed Web of Science ®Google Scholar
• Kramer A, Green J, Pollard J Jr, et al Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523–530.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Guzzi PH, Caracciolo D, et al Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget. 2015;6:19132–19147.
   PubMed Web of Science ®Google Scholar
• Wu P, Agnelli L, Walker BA, et al Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013;162:348–359.
   PubMed Web of Science ®Google Scholar
• Calura E, Bisognin A, Manzoni M, et al. Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget. 2015;7(3):2367–2378.
   Web of Science ®Google Scholar
• Amin SB, Yip WK, Minvielle S, et al. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014;28(11):2229–2234. DOI:10.1038/leu.2014.140
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L, et al Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009;114:e20–e26.
   Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, et al International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210–2221.
   PubMed Web of Science ®Google Scholar
• Agnelli L, Fabris S, Bicciato S, et al Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 2007;136:565–573.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang X, Zheng H, et al Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles. PLoS One. 2013;8:e58809.
   PubMed Web of Science ®Google Scholar
• Furqan M, Akinleye A, Mukhi N, et al STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6:90.
   PubMed Web of Science ®Google Scholar
• Nelson EA, Sharma SV, Settleman J, et al A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget. 2011;2:518–524.
   PubMed Web of Science ®Google Scholar
• Meissner T, Seckinger A, Reme T, et al Gene expression profiling in multiple myeloma–reporting of entities, risk, and targets in clinical routine. Clin Cancer Res. 2011;17:7240–7247.
   PubMed Web of Science ®Google Scholar
• Martino A, Sainz J, Buda G, et al Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J Oncol. 2012;40:625–638.
   PubMed Web of Science ®Google Scholar
• Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma I: effect on risk of multiple myeloma. Eur J Haematol. 2012;88:8–30.
   PubMed Web of Science ®Google Scholar
• Du J, Yuan Z, Zhang C, et al Role of the TNF-alpha promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res. 2010;34:1453–1458.
   PubMed Web of Science ®Google Scholar
• Weinhold N, Johnson DC, Rawstron AC, et al Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood. 2014;123:2513–2517; quiz 2593.
   PubMed Web of Science ®Google Scholar
• Chubb D, Weinhold N, Broderick P, et al Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45:1221–1225.
   PubMed Web of Science ®Google Scholar
• Salazar L, Kashiwada T, Krejci P, et al Fibroblast growth factor receptor 3 interacts with and activates TGFbeta-activated kinase 1 tyrosine phosphorylation and NFkappaB signaling in multiple myeloma and bladder cancer. PLoS One. 2014;9:e86470.
   PubMed Web of Science ®Google Scholar
• Du J, Huo J, Shi J, et al Polymorphisms of nuclear factor-kappaB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica. 2011;96:729–737.
   PubMed Web of Science ®Google Scholar
• Lee KM, Baris D, Zhang Y, et al Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol. 2010;85:560–563.
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Menashe I, et al Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol. 2011;29:42–46.
   PubMed Web of Science ®Google Scholar
• Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119:5359–5366.
   PubMed Web of Science ®Google Scholar
• Martino A, Campa D, Jurczyszyn A, et al Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations–an extensive replication of the associations from the candidate gene era. Cancer Epidemiol Biomarkers Prev. 2014;23:670–674.
   PubMed Web of Science ®Google Scholar
• Lajin B, Alachkar A. The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer. 2013;109:1325–1337.
   PubMed Web of Science ®Google Scholar
• Ma L-M, Ruan L-H, Yang H-P. Meta-analysis of the association of MTHFR polymorphisms with multiple myeloma risk. Sci Rep. 2015;5:10735.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplant. 2014;49:1457–1465.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Landi S, Reiman T, et al Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant. 2010;45:1316–1324.
   PubMed Web of Science ®Google Scholar
• Simeon V, Todoerti K, La Rocca F, et al Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine. Int J Mol Sci. 2015;16:17514–17534.
   PubMed Web of Science ®Google Scholar
• Buda G, Ricci D, Huang CC, et al Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2010;89:1133–1140.
   PubMed Web of Science ®Google Scholar
• Johnson DC, Corthals SL, Walker BA, et al Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797–804.
   PubMed Web of Science ®Google Scholar
• Guzzi PH, Agapito G, Di Martino MT, et al DMET-analyzer: automatic analysis of Affymetrix DMET data. BMC Bioinformatics. 2012;13:258.
   PubMed Web of Science ®Google Scholar
• Rotroff D, Jack J, Campbel N, et al. PGxClean: a quality control GUI for the Affymetrix DMET chip and other candidate gene studies with non-biallelic alleles. BioData Mining. 2014;7:24.
   Web of Science ®Google Scholar
• Di Martino MT, Arbitrio M, Leone E, et al Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 2011;12:780–787.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Arbitrio M, Guzzi PH, et al A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol. 2011;154:529–533.
   PubMed Web of Science ®Google Scholar
• Klein TE, Altman RB. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Pharmacogenomics J. 2004;4:1.
   PubMed Web of Science ®Google Scholar